By providing a platform for idea-sharing, Lilly Open Innovation Drug Discovery lowers the barrier for collaborations between investigators working inside and outside an organization. Lilly is dedicated to the goal of becoming part of a Fully Integrated Pharmaceutical Network (FIPNet). A key part of this transformation is to expand the level of collaborative research with universities, institutes, and biotech to fuel innovative discovery.

We hope that investigators from all over the world will take advantage of this resource and that it will open new venues to test novel therapeutic hypotheses and deepen our understanding of complex biological systems.